🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Biogen veteran Doug Williams joins TriArm Therapeutics as CEO to take on CAR T cell market access issues and other challenges buff.ly/4cZzQpH

Ken Song's post-RayzeBio venture Candid: bispecifics for autoimmunity, leveraging Chinese oncology innovation. An Emerging Company Profile by BioCentury's Karen Tkach Tuzman buff.ly/4ghAaD2

BioCentury's latest roundup of management moves: Lucas Montarce named CFO of Eli Lilly. Plus: Yong Ben hired as chief medical and development officer of TheRas, and updates from Orbital, Latigo, AAVantgarde and more $LLY $SAVA buff.ly/4d5rJHX

Biosecure passes House but Senate fate uncertain: Opposition from Democrats, including Reps Auchincloss, McGovern, could lead Senate to modify or set aside the legislation buff.ly/4gmctcD

Akeso’s bispecific, Vaxcyte & Woodcock’s quality mindset: BioCentury’s latest podcast buff.ly/4ejDkUP

Will bispecifics be the drugs to dethrone cancer's biggest blockbusters? Akeso's ivonescimab took on Keytruda in a head-to-head Phase III study in China, and won. buff.ly/3MENfso

Former FDA leader Janet Woodcock joining effort to advance pharma industry quality buff.ly/47mbQvJ

Deals report: Roivant sets up Pulmovant to advance hypertension therapy from Bayer deal. Plus: Candid joining two newcos to focus on autoimmune bispecifics, and updates from Eli Lilly, Haya, Genetic Leap and more buff.ly/4eghvpb

BioCentury's latest roundup of management moves. Vir names Jason O’Byrne CFO. Plus: Maslowski to become CEO of Forge as Miller steps down, and updates from Abingworth, Sofinnova Partners, PATH and more $VIR $GERN buff.ly/3zbER0w

$TERN has promising data for oral #GLP1 agonist TERN-601 in #obesity with 4.9% placebo-adjusted weight loss at 4 weeks; but that still falls short of what $ROG.SW showed with CT-996 this year buff.ly/4edpEL2

Amy Abernethy and Brad Hirsch create Highlander Health to advance learning healthcare system. buff.ly/47momv4

Passage of bill targeting Chinese CDMOs dents WuXi AppTec, WuXi Biologics stocks buff.ly/4giWooe

The high dose required to generate potential best-in-class efficacy for oral #amycretin highlights the manufacturing and commercial supply challenges that face oral peptide therapies in #obesity $NVO $LLY $VKTX $GPCR #amylin #GLP1 #EASD2024 buff.ly/3B8Rlq5

Industry calls on U.S. FDA to clarify, expand the agency's platform technology program buff.ly/3XG3VWM

BioCentury's latest roundup of management moves: Ovid promotes Alexander to COO. Plus: Tyra hires Warner as CMO and updates from Senisca, Closed Loop, NanoSyrinx and more $OVID $TYRA buff.ly/3TrVHiF

Lilly suing FDA to get retatrutide classified as biologic which would delay #IRA price-setting by 4 years. Case tests courts' post-Chevron deference to agency. buff.ly/3TqcEKa

This week's BioCentury Venture Report features large rounds for Candid, Superluminal and PanTera; plus fundings for Vironexis, Radiant, Bambusa, OrsoBio and F2G buff.ly/4gqaeoC

BioCentury's latest roundup of management moves: Sana CFO Hardy to depart. Plus: New CEOs at Alchemab and Genespire, and more from Leyden and Pharmazz $SANA buff.ly/3BdqCsv

Pharmas step back from first-in-class deals: a BioCentury Data Byte buff.ly/3ZiMJIf

.U.S. FDA label expansions in August include Rybrevant, Jemperli: a BioCentury Data Byte buff.ly/3XKoDFe